INT80983

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1999
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 16
Total Number 18
Disease Relevance 1.95
Pain Relevance 4.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Abcb1b) mitochondrion (Abcb1b) ATPase activity (Abcb1b)
transmembrane transport (Abcb1b)
Anatomy Link Frequency
blood 1
brain 1
internal 1
Abcb1b (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 8 99.92 Very High Very High Very High
Opioid 15 99.18 Very High Very High Very High
Oxycodone 6 99.00 Very High Very High Very High
antinociception 2 98.78 Very High Very High Very High
Analgesic 9 98.30 Very High Very High Very High
Nortriptyline 13 98.28 Very High Very High Very High
Endep 9 98.20 Very High Very High Very High
fluoxetine 5 97.24 Very High Very High Very High
Antinociceptive 1 93.48 High High
methadone 2 88.16 High High
Disease Link Frequency Relevance Heat
Inflammatory Bowel Disease 1 99.52 Very High Very High Very High
Disease 26 98.60 Very High Very High Very High
Targeted Disruption 4 98.56 Very High Very High Very High
Cancer 104 85.52 High High
Primary Sclerosing Cholangitis 3 81.00 Quite High
Myeloid Leukemia 39 76.48 Quite High
Graft Vs Host Disease 1 74.68 Quite High
Leukemia 15 67.92 Quite High
Repression 1 65.56 Quite High
Apoptosis 52 64.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
Regulation (modulation) of P-glycoprotein associated with antinociception, analgesic, enkephalin and opioid
1) Confidence 0.60 Published 1999 Journal Pharm. Res. Section Title Doc Link 10100317 Disease Relevance 0 Pain Relevance 0.98
The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites.
Regulation (influence) of P-glycoprotein associated with nortriptyline
2) Confidence 0.60 Published 2006 Journal Drug Metabol Drug Interact Section Title Doc Link 16841511 Disease Relevance 0.08 Pain Relevance 0.42
PURPOSE: This study was conducted to examine the influence of P-glycoprotein (P-gp) modulation on the pharmacodynamics of the model opioid peptide DPDPE.
Spec (examine) Regulation (modulation) of P-glycoprotein associated with opioid
3) Confidence 0.60 Published 1999 Journal Pharm. Res. Section Abstract Doc Link 10100317 Disease Relevance 0 Pain Relevance 0.32
This unexpected result contradicts a simple model of post-transcriptional or post-translational regulation of MDR1 and was not observed previously in P. falciparum parasites selected in vitro for MF and ART resistance [20], [30].
Regulation (regulation) of MDR1
4) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904698 Disease Relevance 0 Pain Relevance 0
Either of these outcomes could perturb the overall regulation of mdr1 mRNA and protein expression.
Regulation (regulation) of mdr1
5) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904698 Disease Relevance 0.14 Pain Relevance 0
Mice with a genetic disruption (knockout) of the multiple drug resistance (Mdr1a) gene were used to examine the effect of the absence of the drug-transporting P-glycoprotein at the blood-brain barrier on the uptake of amitriptyline (AMI) and fluoxetine (FLU) and their metabolites into the brain.
Spec (examine) Regulation (effect) of P-glycoprotein in blood associated with targeted disruption, endep and fluoxetine
6) Confidence 0.44 Published 2000 Journal Neuropsychopharmacology Section Abstract Doc Link 10700657 Disease Relevance 0.18 Pain Relevance 0.77
Is it possible that the ubp-1 mutation is acting in concert with the mdr1 duplication in determining the ATN + MF resistance phenotype by, for instance, reducing ubiquitination of MDR1 and either allowing its increased turnover or modifying its localisation within the parasite?
Regulation (acting) of mdr1
7) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904698 Disease Relevance 0 Pain Relevance 0
Interestingly, the mdr1 and MDR1 expression data suggest that changes in mdr1 copy number may be accompanied by larger changes in the expression of both mRNA and protein.
Regulation (changes) of mdr1
8) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904698 Disease Relevance 0 Pain Relevance 0
In conclusion, our result shows there has no serious side effect of adenovirus MDR1 gene therapy in short term, which provide useful baseline data for future long-term studies aimed at evaluating the safety of Ad-EGFP-MDR1.


Neg (no) Regulation (effect) of MDR1
9) Confidence 0.34 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2819043 Disease Relevance 0.13 Pain Relevance 0.09
The influence of MDR1 SNP(C3435T and G2677T) on disposition of Pgp substrates or treatment outcome has been examplified in digoxin, phenytoin, fexofenadine, nelfinarvir, cyclosporine, talinolol and loperamide [159].
Regulation (influence) of MDR1
10) Confidence 0.33 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC1277830 Disease Relevance 0.38 Pain Relevance 0.21
Our own preliminary results did not confirm a regulation of p-glycoprotein and MDR-1 but indicate that Abcg2 and the glucose transporter Slc2a1 were notably up-regulated in MBEs by Wnt3aCM (unpublished data).
Regulation (regulation) of p-glycoprotein
11) Confidence 0.26 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2575783 Disease Relevance 0.17 Pain Relevance 0
Downregulation of P-glycoprotein expression with the specific inhibitor verapamil markedly suppressed survivin mRNA expression, whereas no opposite effect of upregulated P-glycoprotein has been reported.
Neg (no) Regulation (effect) of P-glycoprotein
12) Confidence 0.26 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 0.47 Pain Relevance 0
In this study, the effects of hydrocotarnine on the cytochrome P450 (CYP) and P-glycoprotein (P-gp) were investigated.
Regulation (effects) of P-glycoprotein
13) Confidence 0.26 Published 2009 Journal Drug Metab. Pharmacokinet. Section Abstract Doc Link 19252340 Disease Relevance 0 Pain Relevance 0.29
Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein.
Regulation (Effect) of P-glycoprotein
14) Confidence 0.26 Published 2009 Journal Drug Metab. Pharmacokinet. Section Title Doc Link 19252340 Disease Relevance 0 Pain Relevance 0.35
The purpose of this study was to assess quantitatively the influence of mdr1a P-gp on initial brain uptake of chemically diverse opioids in mice.
Regulation (influence) of P-gp in brain associated with opioid
15) Confidence 0.26 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 14698039 Disease Relevance 0.06 Pain Relevance 0.74
Verapamil in the perfusion buffer (0.5 microM) served as a positive control for P-gp-mediated efflux and as an experimental internal standard for P-gp modulation by AR-M delta compounds.
Regulation (modulation) of P-gp in internal
16) Confidence 0.26 Published 2002 Journal J Pharm Sci Section Abstract Doc Link 11782913 Disease Relevance 0 Pain Relevance 0.16
Other experiments by White et al assessing the effect of temperature (37 °C vs 4 °C) on nilotinib uptake and retention in an ABCB1-expressing cell line suggested that nilotinib is transported by ABCB1.
Regulation (effect) of ABCB1
17) Confidence 0.24 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994207 Disease Relevance 0.33 Pain Relevance 0
These observations suggest that the post-translational regulation of MDR1 may be complex.
Regulation (regulation) of MDR1
18) Confidence 0.22 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904698 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox